Notice of Intent to Publish a Funding Opportunity Announcement for Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
Notice Number:

Key Dates

Release Date:
January 11, 2023
Estimated Publication Date of Funding Opportunity Announcement:
May 09, 2023
First Estimated Application Due Date:
November 05, 2023
Earliest Estimated Award Date:
July 01, 2024
Earliest Estimated Start Date:
July 10, 2024
Related Announcements


Issued by

National Institute on Drug Abuse (NIDA)


The National Institute on Drug Abuse intends to re-issue the Funding Opportunity Announcement (FOA) PAR-19-282, Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) .

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in Spring 2023 with an expected application due date in Fall 2023.

This FOA will utilize the R61/R33 activity code. Details of the planned FOA are provided below.

Research Initiative Details

This FOA continues NIDA’s interest in exploratory clinical neuroscience research on substance use disorders (SUD) to support clinical research applications that are in early and conceptual stages of project development and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use (see PAR-19-282 for details).

The FOA will employ the R61/R33 Phased Innovation Award activity code. Support will be provided for up to 5 years, which will include initial support of up to 2 years of the R61 phase, followed by up to 3 years of support for the R33 phase, upon successfully meeting R61 milestones. Preliminary data will not be required; however, applicants may include preliminary data if they are available.

The reissued FOA will continue to seek new and resubmission applications.

Funding Information


Estimated Total Funding

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Expected Number of Awards
Estimated Award Ceiling

For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed $500,000. For the R33 phase, budgets are not limited, but need to reflect the actual needs of the proposed project.

Primary Assistance Listing Number(s)


Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time.


Please direct all inquiries to:

Vani Pariyadath, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: (301) 443-3209

John Fedota, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-402-0812